Selank
Selank Dragon Pharma — Overview
Selank Dragon Pharma is a synthetic heptapeptide anxiolytic and nootropic supplied at 10 mg per lyophilized vial. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank is a stabilized analogue of tuftsin (the endogenous immunoregulatory tetrapeptide Thr-Lys-Pro-Arg) extended by the tripeptide Pro-Gly-Pro to improve metabolic stability. It is registered as a pharmaceutical drug in Russia for the treatment of generalized anxiety disorder and neurasthenia, where it is used as a 0.15% intranasal spray. In performance and cognitive enhancement contexts it is administered subcutaneously from reconstituted research vials, with effects that are more precisely characterized than most compounds in this category due to its well-documented pharmacology.
Selank's primary action is anxiolytic: it reduces anxiety, stress reactivity, and psychological tension without causing sedation, motor impairment, or cognitive blunting — the defining profile that separates it from benzodiazepines and antihistamine-based anxiolytics. Concurrently, Selank upregulates brain-derived neurotrophic factor (BDNF) in the hippocampus and prefrontal cortex, drives nootropic improvements in memory consolidation, learning speed, and sustained attention, and modulates the immune system through cytokine regulation. It does not suppress the HPTA, causes no dependence or rebound anxiety on cessation, and produces no withdrawal syndrome. A standard 10 mg Dragon Pharma vial reconstituted in 5 mL of bacteriostatic water yields 2 mg/mL, providing 40 × 250 mcg doses at the standard protocol dose. Selank is available at Steroid Warehouse alongside its research counterpart Semax Dragon Pharma, the complementary stimulatory nootropic from the same Russian peptide research program.
About the Compound: Selank
Selank (TP-7) is a synthetic analogue of the human endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg), extended at the C-terminus by the sequence Pro-Gly-Pro to improve proteolytic stability and prolong biological activity. Tuftsin is naturally produced by cleavage from the Fc region of IgG and acts as an immunoregulatory signal; its derivatives were studied for anxiolytic and cognitive-enhancing properties because of the overlap between immune signaling peptides and the regulation of stress responses in the central nervous system. Selank's Pro-Gly-Pro extension is not incidental — it blocks the peptidases that would otherwise cleave the parent tuftsin sequence within seconds, extending the effective window of receptor interaction from minutes to hours.
At the molecular level, Selank works through several partially overlapping mechanisms. It inhibits enkephalinase (the enzyme responsible for degrading endogenous enkephalins in the brain), increasing the effective concentration of endogenous opioid peptides in the synaptic cleft without directly binding opioid receptors. It also modulates the GABAergic system — specifically potentiating GABA-A receptor function in a manner that produces anxiolytic effects without the sedation, tolerance, or receptor downregulation associated with benzodiazepine binding at the same receptor; the exact binding site appears to be distinct from the benzodiazepine allosteric site. Additionally, Selank increases expression of BDNF in hippocampal and prefrontal regions, activates serotonergic neurotransmission, and modulates cytokine production (notably IL-6 and interferon) — the immunomodulatory component that is a legacy of its tuftsin origin.
The plasma half-life of Selank after IV administration is approximately 2 minutes, as would be expected for an unprotected peptide; after subcutaneous injection the absorption profile provides a meaningful effective window of 4–6 hours as the peptide is absorbed from the depot and cleared more gradually. The compound does not cross the blood-brain barrier by simple diffusion at the scale of large molecules — it uses receptor-mediated transcytosis pathways, which is why the intranasal route (direct access to olfactory epithelium and CSF) is pharmacologically distinct from subcutaneous administration and both routes are effective.
What Selank Does
- Anxiolytic effect without sedation — Selank reduces anxiety, fear response, and psychological tension through GABAergic modulation and enkephalinase inhibition, producing a state of calm that is described in clinical literature as "tranquilizing without hypnotic effect"; users remain fully alert, cognitively functional, and motor-unimpaired at standard doses; this distinguishes it fundamentally from benzodiazepines (which produce sedation, muscle relaxation, and motor incoordination at anxiolytic doses), antihistamine-based anxiolytics (which cause sedation), and alcohol (which impairs cognition); it can be used during working hours, training, and mentally demanding activity without performance cost
- BDNF upregulation and cognitive enhancement — Selank consistently increases brain-derived neurotrophic factor (BDNF) expression in hippocampal CA1 and CA3 regions and in the prefrontal cortex in preclinical models; BDNF is the primary growth factor supporting synaptic plasticity, long-term potentiation, and memory consolidation; the practical effect is improved memory encoding (information sticks better after learning), faster recall, and enhanced executive function; the nootropic effect is cumulative over 2–4 weeks of daily use and outlasts the cycle, reflecting the durable nature of BDNF-driven synaptic changes rather than an acute neurochemical shift
- Stress resilience and HPA axis modulation — Selank reduces the cortisol stress response and blunts hyperactivation of the HPA axis under conditions of psychological and physical stress without suppressing baseline cortisol to pathological levels; this makes it useful during high-intensity training periods, pre-competition preparation, or high-cognitive-demand work cycles where stress-induced performance degradation is a concern; the adaptogenic profile is more specific than classical adaptogens (ashwagandha, rhodiola) because the mechanism is defined at the receptor level rather than being a general stress-buffer
- Serotonin system modulation and mood stabilization — Selank increases serotonin turnover and modulates 5-HT receptor sensitivity, contributing to mood stabilization and mild antidepressant effects; this component of the profile is relevant for users experiencing mood dysregulation during caloric deficit, PCT, or high training stress; the antidepressant effect is mild and supportive rather than primary — Selank should not be considered a treatment for clinical depression, but its serotonergic contribution is a meaningful addition to the overall neurochemical profile during demanding phases
- Immunomodulatory effect — as a tuftsin analogue, Selank retains meaningful activity at the immune signaling level; it regulates IL-6 and interferon production, modulates T-cell and natural killer cell activity, and reduces inflammatory cytokine expression; this immune-modulating component is the least performance-relevant of Selank's effects for most users but may be significant for those using it during periods of immunosuppression (heavy training, caloric deficit, post-illness recovery) or who combine it with immunomodulatory peptides such as Thymosin Alpha-1
Who It's For
- Athletes experiencing high anxiety, psychological stress, or cognitive fatigue during peak training phases or competition preparation — Selank addresses the CNS side of performance that compounds targeting the musculoskeletal system do not touch; training-induced sympathetic overdrive, pre-competition anxiety, and cognitive fatigue from sustained high-output training phases all respond to Selank's anxiolytic-nootropic profile; critically, it does this without sedating the user or blunting competitive arousal — it normalizes the anxiety that degrades performance without removing the alertness that drives it
- Users on PCT or after a suppressive AAS/SARM cycle experiencing mood dysregulation, anxiety, or cognitive fog — hormonal normalization during PCT is often accompanied by mood instability, anxiety, low motivation, and reduced cognitive clarity that are driven by the drop in androgens and the lag in endogenous testosterone recovery; Selank's serotonergic, GABAergic, and BDNF-upregulating effects directly address these CNS consequences of hormonal transition without interfering with the PCT compounds (SERMs, aromatase inhibitors) or the HPTA recovery process itself; it is the most pharmacologically appropriate peptide support compound for PCT-associated psychological symptoms
- What differentiates Selank from similar alternatives: vs Semax Dragon Pharma — Semax is the stimulatory counterpart to Selank from the same Russian research program; where Selank produces calm anxiolytic focus, Semax drives alert, activated, stimulatory cognitive enhancement; users with high anxiety, stress reactivity, or sleep disruption typically respond better to Selank; users needing drive, motivation, and mental activation with minimal anxiety do better with Semax; the two are commonly stacked together (Selank morning for calm sustained focus, Semax as needed for acute cognitive activation) because their mechanisms are complementary rather than redundant
- Users who should choose something else: users whose primary need is sleep improvement (rather than daytime anxiety) should start with DSIP Dragon Pharma (delta sleep-inducing peptide) before adding Selank; users who need primarily cognitive activation and drive with no anxiety component are better served by Semax standalone; users expecting significant fat loss, muscle building, or hormonal effects should not rely on Selank — it has no direct anabolic, androgenic, or lipolytic activity
Selank vs Alternatives
| Compound | Key Differences | Choose Selank When | Choose Alternative When |
|---|---|---|---|
| Semax Dragon Pharma | ACTH(4-7) analogue; stimulatory nootropic with strong cognitive activation, drive, and motivation effects; increases dopamine, norepinephrine, and BDNF; produces alert, energized mental state; does not primarily reduce anxiety — can temporarily amplify anxiety in high-stress contexts; complementary rather than competing mechanism to Selank; the classical pairing is Selank morning for anxiolytic calm focus + Semax as-needed for acute cognitive activation; both upregulate BDNF but through different receptor pathways and with different experiential profiles | Primary need is anxiety relief combined with calm, sustained focus; stress reactivity, overactivation, PCT mood support; users sensitive to stimulatory nootropics | Cognitive activation, drive, and motivation are the primary needs; anxiety is not a concern; looking for stimulatory rather than calming cognitive enhancement; stack with Selank for complementary combined profile |
| Epitalon Dragon Pharma (Epithalon) |
Tetrapeptide telomerase activator targeting longevity and anti-aging endpoints (telomere preservation, circadian rhythm normalization, pineal gland regulation); extends telomere length in vitro and in animal studies; improves sleep quality and melatonin secretion; no direct anxiolytic or acute nootropic effect; acts over months rather than weeks; represents an entirely different use case — cellular longevity vs acute CNS function; occasionally used together with Selank in combined longevity + cognitive optimization protocols | Acute anxiety relief and short-cycle cognitive enhancement are the goals; 2–4 week protocol window; performance cycle support | Long-term anti-aging, telomere health, and circadian normalization are the goals; sleep improvement as a primary endpoint; user is running a longevity-focused protocol extending over 1–3 months |
| DSIP Dragon Pharma (Delta Sleep-Inducing Peptide) |
Neuropeptide that promotes slow-wave delta sleep by modulating sleep architecture at the thalamic and hypothalamic level; reduces sleep onset latency, increases total sleep time, and normalizes disrupted sleep from training stress, shift work, or stimulant use; also shows mild stress-buffering and anti-oxidant effects; unlike Selank, it is primarily a sleep compound rather than a daytime anxiolytic; does not produce daytime focus or cognitive enhancement; most useful at night to address training-induced sleep disruption | Daytime anxiety relief, cognitive performance, and focus enhancement are the priority; anxiety rather than insomnia is the dominant complaint; user needs daytime functionality | Sleep quality, sleep onset, and recovery from training-induced insomnia are the primary concerns; stimulant or thermogenic use is disrupting sleep; DSIP addresses nighttime recovery while Selank addresses daytime function — they can be stacked (Selank daytime, DSIP at night) |
Dosing & Reconstitution
| Step | Details |
|---|---|
| Reconstitution | Add 5 mL bacteriostatic water to the 10 mg vial using a clean insulin syringe; inject BAC water slowly down the side of the vial without directly hitting the lyophilized powder cake; swirl gently to dissolve — do not shake; resulting concentration: 2 mg/mL (2000 mcg/mL). Alternatively: 10 mL BAC water → 1 mg/mL (1000 mcg/mL) for easier small-volume measurement. Do not use sterile saline (no bacteriostatic agent = shorter shelf life after reconstitution) |
| Standard Dose (250 mcg) | At 2 mg/mL: draw 0.125 mL (12.5 units on a U-100 insulin syringe). At 1 mg/mL: draw 0.25 mL (25 units). Inject subcutaneously into the lower abdomen or lateral thigh. Pinch skin, insert at 45°, inject slowly. Once daily in the morning, or split into morning + early afternoon |
| Higher Dose (500 mcg) | At 2 mg/mL: draw 0.25 mL (25 units). At 1 mg/mL: draw 0.5 mL (50 units). Used by experienced users or when 250 mcg/day produces insufficient anxiolytic response. Split into two 250 mcg injections (morning + noon) rather than a single 500 mcg bolus to smooth the effect curve and avoid any peak-dose side effects |
| Vial Yield (10 mg vial at 5 mL / 2 mg/mL) | At 250 mcg/dose: 40 doses per vial — 40 days at once daily, or 20 days at BID. At 500 mcg/dose: 20 doses per vial — 20 days at once daily, or 10 days at BID. A standard 3-week protocol at 250 mcg/day uses 5.25 mg (roughly half the vial) |
| Storage after reconstitution | Refrigerate at 2–8°C immediately after reconstitution. Protect from light. Use within 28–30 days. Do not freeze reconstituted peptide. Lyophilized (unreconstituted) vials: store at 2–8°C; stable for the shelf-life period on the vial |
Side Effects & Management
Selank has one of the cleanest side-effect profiles of any anxiolytic compound, which is the practical consequence of its distinct mechanism from benzodiazepines and classical sedative-hypnotics. The adverse effect list documented in clinical trials is minimal.
| What May Occur | Background | How to Handle It |
|---|---|---|
| Mild sedation or drowsiness (rare) | Selank is specifically documented as non-sedating at standard doses; mild drowsiness is occasionally reported by first-time users in the first 1–3 days, likely reflecting the anxiolytic effect being experienced as unfamiliar relaxation rather than true pharmacological sedation; resolves spontaneously as the user adjusts; not a dose-limiting effect for most users; if it does occur, it indicates appropriate anxiolytic action | Start with 250 mcg once daily in the morning to assess tolerance; if mild drowsiness occurs, take the injection with food and assess over 3–5 days; sedation that persists beyond day 5 is atypical and warrants dose reduction to 100–150 mcg/day |
| Injection site discomfort | Mild stinging or redness at the subcutaneous injection site; common to SC peptide injections generally and not specific to Selank; caused by the pH and osmolarity of the reconstituted solution; transient, resolves within 10–20 minutes; no tissue damage or long-term local effects at standard injection volumes | Rotate injection sites across the lower abdomen and lateral thighs; use the smallest gauge insulin needle available (28–31G); ensure BAC water is used (not plain saline or water for injection); inject slowly and at room temperature rather than cold from the refrigerator; warming the syringe briefly in hand before injection reduces site discomfort |
| Initial anxiety paradox (rare, first 1–3 days) | A small number of users report a brief increase in anxiety or restlessness in the first 1–3 doses before the anxiolytic effect establishes; believed to reflect initial GABAergic modulation before the full receptor adaptation occurs; described in the published literature for benzodiazepine-adjacent compounds as an initial paradoxical excitation; resolves within the first 3–5 days of consistent use as the neuroadaptive effect stabilizes | Start at 100–150 mcg/day for the first 3 days rather than 250 mcg; escalate to 250 mcg after initial tolerance confirmation; do not discontinue based on first-dose response — the anxiolytic effect is typically established by day 4–7 of consistent use |
| No rebound anxiety, no withdrawal | Unlike benzodiazepines, which cause significant rebound anxiety and physical withdrawal syndrome on cessation, Selank cessation produces no documented rebound anxiety, no physical withdrawal, and no tolerance that requires dose escalation; the GABAergic modulation involved does not cause receptor downregulation in the same manner as direct GABA-A agonists; this is one of the most clinically relevant distinctions from pharmacological anxiolytics and represents a fundamental safety advantage for repeated or extended use | No taper required when stopping; no off-period management needed; cycle can be ended abruptly; the BDNF-driven nootropic effects may persist 1–4 weeks after the last dose due to the durable nature of synaptic changes driven by BDNF upregulation |
Bloodwork Monitoring
Selank requires minimal formal bloodwork monitoring due to its narrow mechanism and absence of endocrine, hepatic, or lipid effects. The following serves as a practical reference rather than a mandatory panel.
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| Cortisol (serum, morning) | Optional; useful for users specifically using Selank for stress/HPA axis management; baseline + end of a 4-week cycle | Normal morning cortisol: 6–23 mcg/dL (138–635 nmol/L); Selank modulates stress-driven cortisol elevation without suppressing basal cortisol; baseline measurement is useful to confirm whether anxiety is cortisol-driven and to document response; values below 6 mcg/dL at baseline suggest adrenal insufficiency unrelated to Selank |
| Comprehensive metabolic panel | Not specifically required for Selank; include in any routine annual health panel | Selank has no documented hepatotoxic, nephrotoxic, or electrolyte-disrupting effects; liver enzymes (ALT, AST), creatinine, and electrolytes are unaffected by standard Selank protocols; no Selank-specific thresholds apply |
| LH, FSH, total testosterone (if stacking with AAS/SARMs) | Standard AAS/SARM monitoring schedule — not driven by Selank | Selank does not contribute to HPTA suppression and does not alter these values; if on a combined protocol, monitor per the suppressive compound's requirements; Selank has no impact on these markers |
Cycle Structure
Selank can be used as a short acute protocol (1–2 weeks for a specific high-stress period) or as a medium-duration cognitive cycle (3–4 weeks for cumulative BDNF and nootropic effects). The two approaches have different rationale and different optimal doses.
| Cycle | Protocol | Notes |
|---|---|---|
| Acute anxiety management (1–2 weeks) | 250–500 mcg/day for 1–2 weeks; once daily or BID; taken during a specific high-stress window (pre-competition, exam period, high training volume block) | Full anxiolytic effect is present from dose 1–3; no loading phase required; the 1–2 week duration is sufficient for acute anxiety management without requiring cumulative BDNF effects; after 2 weeks: 1–2 week off period before repeating |
| Nootropic cycle (3–4 weeks) | 250 mcg/day for 3–4 weeks; once daily in the morning; off for 2 weeks; repeat as needed | The nootropic (memory, learning, executive function) effect is cumulative and requires 2–3 weeks to fully establish via BDNF upregulation; 3–4 weeks on allows BDNF-driven synaptic changes to consolidate; the cognitive benefit outlasts the cycle by 1–4 weeks; this is the preferred protocol for cognitive optimization use cases |
| PCT support | 250 mcg/day starting week 1 of PCT; continue for the full PCT duration (typically 4–6 weeks); no overlap extension beyond PCT completion required | PCT-associated mood dysregulation, anxiety, and cognitive fog begin in week 1–2 post-cycle as androgens drop; Selank should start simultaneously with PCT compounds (Nolvadex, Clomid) to address the CNS consequences of hormonal decline from the outset; no pharmacokinetic interaction with SERMs or aromatase inhibitors; stop Selank when PCT completes or when mood has normalized |
| Stack with Semax | Selank 250 mcg morning (anxiolytic baseline) + Semax 100–200 mcg as needed for acute cognitive activation (typically before demanding cognitive work) | The classic Selank+Semax stack exploits the complementary profiles: Selank handles the anxiety floor while Semax provides the activating cognitive ceiling; users report clean, focused, high-output mental performance without the edginess of Semax alone or the sedation concern of Selank at high doses; this is the most commonly reported peptide nootropic stack in Russian research peptide communities |
Practical Summary
- Reconstitute with bacteriostatic water only: BAC water (0.9% benzyl alcohol preserved) is mandatory for multi-use vials; plain sterile water or saline has no bacteriostatic agent and should only be used for single-dose use; 5 mL BAC water into a 10 mg vial gives 2 mg/mL — the most practical working concentration; store reconstituted vial refrigerated and use within 28–30 days
- Expect the nootropic effect to build over 2–3 weeks: the anxiolytic effect (calm, reduced tension) is present from the first few doses; the memory and learning improvements take 2–3 weeks to fully appear because they are driven by BDNF upregulation and synaptic remodeling, not an acute neurochemical shift; don't judge the nootropic component after 3 days
- Stack Selank + Semax for complementary full-spectrum nootropic coverage: Selank morning for sustained anxiolytic calm focus; Semax as needed for cognitive activation, drive, and motivation; the two compounds address opposite poles of cognitive performance and combine without mechanism redundancy or pharmacokinetic interaction
- For PCT use, start day 1 of PCT — not after symptoms appear: Selank's serotonergic and GABAergic effects take 4–7 days to establish their anxiolytic baseline; starting at PCT week 1 means the full effect is active before the worst mood dysregulation typically arrives (weeks 2–3 post-cycle); starting only after symptoms appear means tolerating the worst of the PCT window unprotected
- No taper, no withdrawal management: Selank can be stopped abruptly at the end of any cycle without rebound anxiety, sleep disruption, or any discontinuation syndrome; the BDNF-driven cognitive benefit may persist for 1–4 weeks post-cycle; no clinical management is required at cycle end
Selank Dragon Pharma occupies a specific and well-defined role among research peptides: it is the primary anxiolytic nootropic for athletes and users who need to manage stress, anxiety, and cognitive performance without sedation, endocrine disruption, or dependence risk. Its pharmacological basis in GABAergic modulation and BDNF upregulation gives it a clinical logic that distinguishes it from most supplements in this category, and its combination profile with Semax makes it a foundational pairing for anyone building a serious cognitive enhancement protocol. Available at Steroid Warehouse alongside its complementary peptides.
References
| Source | Topic | Link |
|---|---|---|
| Eksperimental'naya i Klinicheskaya Farmakologiya / PubMed | Semenova et al. 2010 — experimental study of Selank effects on learning and memory processes; supports Selank's nootropic research profile through memory-trace stability and cognitive-performance observations in preclinical models | Semenova TP, et al. (2010) ↗ |
| Bulletin of Experimental Biology and Medicine / PubMed | Zozulya et al. 2001 — study of Selank's inhibitory effect on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity; supports the enkephalinase-related mechanism behind Selank's anti-anxiety pharmacology | Zozulya AA, et al. (2001) ↗ |
| Doklady Biological Sciences / PubMed | Inozemtseva et al. 2008 — intranasal Selank regulation of BDNF expression in the rat hippocampus in vivo; supports a possible neurotrophic mechanism related to hippocampal plasticity and memory biology | Inozemtseva LS, et al. (2008) ↗ |
| Eksperimental'naya i Klinicheskaya Farmakologiya / PubMed | Narkevich et al. 2008 — comparative study of Selank effects on monoamines and their metabolites in BALB/c and C57Bl/6 mouse brain structures; supports Selank's interaction with serotonin, dopamine, and norepinephrine-related neurochemical pathways | Narkevich VB, et al. (2008) ↗ |
| Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova / PubMed | Medvedev et al. 2014 — comparative clinical study of Selank and phenazepam in patients with anxiety disorders; reports anxiolytic and mild nootropic effects with favorable tolerability, but should not be described as a placebo-controlled Psychopharmacology trial | Medvedev VE, et al. (2014) ↗ |
What is Selank?
Selank is an anxiolytic peptide for stress relief and cognition; see What is Selank. It enhances mental clarity—consult professionals for safe use.
What is Selank used for?
It's used for anxiety reduction and cognitive enhancement; see Key Benefits. It suits wellness goals—use with professional oversight.
What does Selank do?
It reduces stress and boosts focus via serotonin and BDNF modulation; see Mechanism of Action. It supports mental health—monitor with professional guidance.
What is Selank peptide used for?
It's used for stress relief, mood improvement, and cognitive support; see Key Benefits. It's ideal for high-stress training—consult professionals.
Is Selank safe?
It's safe with proper dosing and monitoring, but not FDA-approved; see Side Effects. Manage risks with professional guidance—consult for safety.
What are the main benefits of Selank?
Commonly discussed benefits include reduced stress, improved emotional stability, enhanced focus, better cognitive performance, and support for overall mental resilience.
What are the possible side effects of Selank?
Available research suggests Selank is generally well tolerated, though some individuals may experience mild irritation, temporary fatigue, or headaches.
What makes Selank different from other nootropic peptides?
Selank is unique because it is often associated with promoting relaxation and emotional balance without significant sedation, while also supporting cognitive function and mental performance.
Related Products
- Accelerates muscle and tendon repair for quick recovery.
- Reduces inflammation systemically and locally.
- Enhances joint and tissue resilience for intense training.
- Supports comprehensive healing for uninterrupted performance.
